Core Insights - The Chemours Company reported a net loss of $47 million or 31 cents per share for Q4 2025, a significant decline from the previous year's net loss of $11 million or 8 cents [1] - Adjusted EBITDA decreased by 24% year over year to $128 million, primarily due to weaker performance in Titanium Technologies and Advanced Performance Materials segments [3] Financial Performance - Q4 net sales were $1,329 million, reflecting a 2.2% decline from the previous year, in line with Zacks Consensus Estimate [2] - Cash provided by operating activities was $137 million, slightly down from $138 million in the prior quarter, while capital expenditures were reduced to $45 million from $109 million year over year [8] Segment Performance - Titanium Technologies division revenues were $561 million, an 11% decrease year over year, but exceeded estimates [4] - Thermal & Specialized Solutions segment saw a 14% year-over-year revenue increase to $444 million, driven by higher prices and volume [5] - Advanced Performance Materials unit revenues amounted to $312 million, a 4% decline year over year, primarily due to an 8% decrease in volume [7] Outlook - The company expects Q1 sales to increase by 3-5% sequentially, with full-year sales growth projected at 3-5% year over year [9] - Adjusted EBITDA is anticipated to be between $120-$150 million for Q1 and $800-$900 million for 2026 [9] - The Titanium Technologies segment is expected to see a sequential decline in net sales, while Thermal & Specialized Solutions is projected to experience a mid-20 to 30% sequential increase [11][12] Stock Performance - Chemours shares have gained 5.5% over the past year, contrasting with a 13.4% decline in the industry [13]